x Health Men's Health Children's Health Nutrition and Wellness Reproductive Health Health & Science Digital News Videos Opinions Cartoons Education E-Paper Lifestyle & Entertainment Nairobian Entertainment Eve Woman Travelog TV Stations KTN Home KTN News BTV KTN Farmers TV Radio Stations Radio Maisha Spice FM Vybez Radio Enterprise BULK SMS E-Learning Digger Classified The Standard Group Corporate Contact Us Rate Card Vacancies DCX O.M Portal Corporate Email RMS
Login ×
BTV
VAS
DCX
RMS

Gilead's Covid-19 antiviral remdesivir gets conditional EU clearance

Health & Science - By Reuters | July 4th 2020 at 08:48:32 GMT +0300

FILE PHOTO: Gilead Sciences Inc pharmaceutical company is seen after they announced a Phase 3 Trial of the investigational antiviral drug Remdesivir in patients with severe coronavirus disease (COVID-19), during the outbreak of the coronavirus disease (Covid-19), in Oceanside, California, US, April 29, 2020. [Reuters]

The European Commission said on Friday it had given conditional approval for the use of antiviral remdesivir in severe COVID-19 patients following an accelerated review process, making it the region’s first authorised therapy to treat the virus.

The move comes just a week after the European Medicines Agency (EMA) gave its go-ahead for the drug, produced by Gilead Sciences (GILD.O), to be used in adults and adolescents from 12 years of age who are also suffering from pneumonia and require oxygen support.

It also comes just days after the company allocated nearly all of its supply of remdesivir to the United States over the next three months, stirring concerns about availability elsewhere.

“We will leave no stone unturned in our efforts to secure efficient treatments or vaccine against the coronavirus,” said Stella Kyriakides, EU Commissioner for Health and Food Safety, in a statement.

Covid 19 Time Series

 

The Commission said on Wednesday it was in negotiations with Gilead to obtain doses of remdesivir for the 27 European Union countries.

Remdesivir is in high demand after the intravenously-administered medicine helped to shorten hospital recovery times in a clinical trial.

It is believed to be most effective in treating Covid-19 patients earlier in the course of disease than other therapies like the steroid dexamethasone.

Still, because remdesivir is given intravenously over at least a five-day period it is generally being used on patients sick enough to require hospitalisation.

The EU’s green light broadens the use of remdesivir around the world - the United States has cleared it for emergency use and it is also approved as a Covid-19 therapy in Japan, Taiwan, India, Singapore and the United Arab Emirates, Gilead said on Friday.

A conditional marketing authorisation is one of the EU regulatory mechanisms created to facilitate early access to medicines that fulfil an unmet medical need, including those for emergency situations in response to public health threats such as the current pandemic, the Commission said.

The approval is valid for one year in the bloc and can be extended or converted into an unconditional marketing authorisation if all necessary data are available on its efficacy and side effects.

The agency reviews data as they become available on a rolling basis, while development is still ongoing. The EMA’s rolling review began at the end of April.

Top Stories

COVID-19 shots to cost between Sh300 and Sh1100 under African Union vaccine plan
Health & Science - By Reuters


80 test positive for coronavirus in Kenya today
Health & Science - By Jael Mboga


Woman's cry for justice after losing uterus in wrong surgery
Health & Science - By Mactilda Mbenywe


Covid-19: Kenya records 136 new cases as 176 recover
Health & Science - By Judah Ben-Hur


No coronavirus deaths in Kenya today - Health ministry
Health & Science - By Jael Mboga


We'll go on with strike, healthcare workers say
Health & Science - By Anyango Otieno and Kirsten Kanja


Medication mistakes you should avoid
Health & Science - By Standard Digital


Alcoholism blamed for high TB prevalence in Kiambu
Health & Science - By Kamau Maichuhie


Sampuli ya magonjwa yanayoathiri viungo mwilini
Health & Science - By Is`haq Gunga Chea


Latest Stories

We'll go on with strike, healthcare workers say
Health & Science - By Anyango Otieno and Kirsten Kanja


COVID-19 shots to cost between Sh300 and Sh1100 under African Union vaccine plan
Health & Science - By Reuters


Covid-19: Kenya records 136 new cases as 176 recover
Health & Science - By Judah Ben-Hur


Muslim Council calls on governors to heal health crisis
Health & Science - By Judah Ben-Hur


I eagerly await my baby's first steps
Health & Science - By Mactilda Mbenywe


President urges striking medics to return to work
Health & Science - By Wainana Ndung’u and Kennedy Gachuhi


No coronavirus deaths in Kenya today - Health ministry
Health & Science - By Jael Mboga


A virus that reverses deafness
Health & Science - By Killiad Sinide


I survived the deadliest cancer
Health & Science - By Yvonne Kawira


 When should you be worried about delayed milestones?
Health & Science - By Nancy Nzalambi


//

Stay Ahead!

Access premium content only available
to our subscribers.

Or Login With Your Standard Account
Support independent journalism
×
Create An Account
Support independent journalism
I have an account Log in
Reset Password
Support independent journalism
Log in